Thierry Judge, a master’s student in the Department of Computer Science at the University of Sherbrooke, has developed a technology that identifies when results generated by emerging artificial intelligence (AI) systems — which speed up analysis of ultrasound images to detect heart disease — are incorrect or uncertain. The software, called CRISP, is currently being tested by Oxford, UK-based, Ultromics Ltd, a leader in AI echocardiography.
A lack of innovation in prosthetics in recent decades means opportunity for Halifax start-up Awenza Health Inc. Founded two years ago, the company is working to disrupt the prosthetics market and provide better solutions for patients through new technologies.
Many current products on the market, says CEO Sam Awara, cause high levels of discomfort and even pain in some situations. So Awenza is building a suite of products to solve these issues for those with limb differences.
Karina Gasbarrino uses AI to tackle the second-leading cause of death and third-leading cause of disability worldwide – stroke. Her journey started more than a decade ago when she lost her grandfather to a sudden stroke. Since then, she has devoted her academic career to his memory, helping to advance early detection and diagnosis of harmful fatty deposits in the arteries of the neck. Rupturing of these plaques is the main cause of strokes.
There are significant mental health disparities between Indigenous and non-Indigenous people in Canada, largely due to a legacy of colonization. Though Indigenous health is legally a federal responsibility, mental health services vary dramatically between provinces and territories.
Gustavo Betini, a PhD student in the school of Public Health Science at the University of Waterloo, has spent the past year immersed in studying the mental health effects of COVID-19. His research has shown that, even though fear of contracting the virus is waning, almost a quarter of Canadians continue to report having high anxiety and depression related to the pandemic.
Structural Genomics Consortium (SGC), the Canadian-led consortium of pharmaceutical companies, clinicians and academia, supports open-access drug discovery around the world. And it’s bringing hope to the 300 million people afflicted by rare diseases and a world ravaged by COVID-19.
The COVID-19 pandemic sparked an urgent need for innovation in all aspects of our lives – and researchers rose to the challenge. From COVID-19 diagnostics and treatments to changes in how we work and receive healthcare, the pandemic has fast-tracked innovation across sectors.
High-potential researchers and businesses around the world did a pandemic pivot, shifting their work and resources to respond to the world’s pressing need for solutions. In Canada, Seyyedarash (Arash) Haddadi’s story is a standout example of innovation partnerships helping to counter the COVID-19 threat.
Many of Canada’s most pressing public health issues are complex and significantly affected by factors such as gender and sexism, systemic racism, economic inequality, and other social determinants. African, Caribbean, and Black (ACB) communities have long been unfairly affected by health inequity due to historic racism and on-going disparities built into governmental, financial, and educational institutions.
Sofia Addab, Jean-Gabriel Lacombe, and Georgia Powell are master’s students in the Department of Experimental Surgery at McGill University in Montréal. During a shared internship shadowing medical staff in the emergency room at the Montreal Children’s Hospital, the trio quickly identified that the time-consuming practice of calculating correct doses of IV medication by hand was leading to potential mistakes and disrupting workflow at critical points during the intake of trauma cases in the hospital’s emergency room, posing serious safety risks to children.